Tyrosine Kinase Inhibitors: all 10,744 studies that test it

Page 100 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.

• Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast CancerWithdrawnNCT00615524Phase 2
• A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid TumorsCompletedNCT00615446Phase 1
• Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast CancerCompletedNCT00614978Phase 1
• Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung CancerStatus unknownNCT00614809Phase 2
• Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic CancerCompletedNCT00614653Phase 1
• Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant GliomasCompletedNCT00613223Phase 1
• Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid TumorsCompletedNCT00613145Phase 1
• Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant GliomaCompletedNCT00613054Phase 1
• A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid TumorsCompletedNCT00612703Phase 1
• A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid TumorsCompletedNCT00612209Phase 1
• PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced MalignanciesCompletedNCT00611793Phase 1
• Ph I SU011248 + Irinotecan in Treatment of Pts w MGCompletedNCT00611728Phase 1
• A Study of Radiation With Sorafenib in Advanced CancerCompletedNCT00610246Phase 1
• Ph I Dasatinib + Erlotinib in Recurrent MGCompletedNCT00609999Phase 1
• Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the BoneCompletedNCT00609934Phase 1/2
• A Phase 1 Study of ARQ 197 in Patients With Solid TumorsCompletedNCT00609921Phase 1
• Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
• A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast CancerTerminatedNCT00607438Phase 2
• Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid TumorsTerminatedNCT00607399Phase 1
• Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid TumorsTerminatedNCT00606879Phase 1
• MRI Study of BAY 43-9006 in Metastatic Renal Cell CarcinomaCompletedNCT00606866Phase 3
• Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid TumorsCompletedNCT00606125Phase 1
• Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT00605618Phase 1/2
• Phase I Study of OSI-930 and Erlotinib in Cancer TumorsCompletedNCT00603356Phase 1
• Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250CompletedNCT00602862Not applicable
• Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by SurgeryCompletedNCT00601913Early Phase 1
• Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By SurgeryWithdrawnNCT00601614Phase 1
• Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach CancerCompletedNCT00601510Phase 1
• Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00600587Phase 2
• Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- TarcevaCompletedNCT00598156Phase 3
• A Phase I/Expansion Study of DasatinibTerminatedNCT00598091Phase 1
• Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric CancerTerminatedNCT00595985Phase 2
• A Phase 1 Study of XL019 in Adults With Polycythemia VeraTerminatedNCT00595829Phase 1
• Phase I/II Combination With Irinotecan- ErbituxCompletedNCT00594984Phase 1/2
• A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid LeukemiaWithdrawnNCT00594555Phase 2
• Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid TumorsCompletedNCT00591383Phase 1
• Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine TumorsCompletedNCT00590343Phase 2
• Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential ThrombocytosisCompletedNCT00586651Phase 2
• Interaction Study of Rapamycin and Sunitinib in Patients With Advanced CancersCompletedNCT00583063Early Phase 1
• Erlotinib and Sunitinib in NSCLCCompletedNCT00581789Phase 1
• Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male SubjectsCompletedNCT00578916Phase 1
• SU011248 for Platinum-Refractory Urothelial Cancer Evaluation TrialCompletedNCT00578526Phase 2
• Erlotinib and Everolimus in Treating Patients With Metastatic Breast CancerCompletedNCT00574366Phase 1
• Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal TumorsTerminatedNCT00573404Phase 1
• Low-Dose Oral Imatinib for Scleroderma Pulmonary InvolvementStatus unknownNCT00573326Phase 2
• Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid TumorsCompletedNCT00572078Phase 1
• A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or SunitinibCompletedNCT00570635Phase 2
• The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic SyndromeWithdrawnNCT00570375Phase 2
• Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid TumorsCompletedNCT00569036Phase 1
• Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)Status unknownNCT00568841Phase 2
• Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal TumorsCompletedNCT00568750Phase 2
• Erlotinib in Treating Patients With Barrett EsophagusStatus unknownNCT00566800Phase 1
• Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or LegCompletedNCT00565968Phase 1
• Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic CancerCompletedNCT00565487Phase 1
• Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by SurgeryCompletedNCT00563823Phase 2
• A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell CarcinomaCompletedNCT00563147Phase 1
• Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and DoxorubicinCompletedNCT00562913Phase 1
• Sorafenib/Docetaxel Dose Escalation TrialCompletedNCT00562523Phase 1
• A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid TumorsTerminatedNCT00560716Phase 1
• A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)CompletedNCT00559182Phase 1
• Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia PatientsTerminatedNCT00558961Phase 1/2
• A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic AdenocarcinomaCompletedNCT00558207Phase 2
• Phase 2 Study in Patients With MiT TumorsCompletedNCT00557609Phase 2
• Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant PatientsWithdrawnNCT00556257Phase 2
• Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell CarcinomaWithdrawnNCT00556205Phase 2
• A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00555256Phase 1
• WBRT & Erlotinib in Advanced NSCLC and Brain MetastasesTerminatedNCT00554775Phase 2
• A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor PatientsCompletedNCT00551850Phase 1
• A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant MesotheliomaStatus unknownNCT00551252Phase 2
• Gemcitabine/Capecitabine/ZD6474 in Advanced Solid TumorsCompletedNCT00551096Phase 1
• Sutent Maintenance After Response to TaxotereStatus unknownNCT00550810Phase 2
• Study Evaluating Oral Administrations of HKI-272 in Healthy Male SubjectsCompletedNCT00550212Phase 1
• Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast CancerCompletedNCT00548899Phase 2
• Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung CancerWithdrawnNCT00547443Phase 1/2
• Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate CancerStatus unknownNCT00546039Phase 2
• Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2CompletedNCT00544804Phase 1
• Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative IntentCompletedNCT00544609Phase 1
• Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal CancerCompletedNCT00543842Phase 1
• Bevacizumab in Multiple Phase I CombinationsCompletedNCT00543504Phase 1
• Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung CancerTerminatedNCT00543335Phase 1
• Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase InhibitorCompletedNCT00543049Phase 2
• Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue SarcomaStatus unknownNCT00541840Phase 1/2
• Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerStatus unknownNCT00541021Phase 3
• Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell CancerCompletedNCT00541008Phase 2
• Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal CancerCompletedNCT00540943Phase 1
• Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer PatientsTerminatedNCT00539331Phase 1
• An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT00538109Not applicable
• Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant MelanomaStatus unknownNCT00538005Phase 1/2
• Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung CancerCompletedNCT00536861Phase 1
• A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic CancerSuspendedNCT00536770Phase 2
• Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus BevacizumabCompletedNCT00536640Phase 2
• A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced CancerCompletedNCT00535522Phase 1
• SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma MultiformeStatus unknownNCT00535379Phase 2
• BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00533585Phase 1
• ZD6474 Alone and in Combination With Retinoic Acid in Pediatric NeuroblastomaTerminatedNCT00533169Phase 1
• Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal CancerCompletedNCT00532909Phase 1
• An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian CancerStatus unknownNCT00532194Phase 3
• Sorafenib in Resected Non-small Cell Lung CarcinomaTerminatedNCT00532025Phase 2
• A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248CompletedNCT00531544Not applicable
• MAAM Study: Avastin and Macugen Versus Avastin Versus MacugenCompletedNCT00531336Phase 2

← Tyrosine Kinase Inhibitors overview